Epigallocatechin-3-gallate reduces the proliferation of benign prostatic hyperplasia cells via regulation of focal adhesions


ERBAYKENT TEPEDELEN B., Soya E. , Korkmaz M.

LIFE SCIENCES, vol.191, pp.74-81, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 191
  • Publication Date: 2017
  • Doi Number: 10.1016/j.lfs.2017.10.016
  • Title of Journal : LIFE SCIENCES
  • Page Numbers: pp.74-81
  • Keywords: EGCG, BPH, Cytoskeleton, F-Actin, FAK, Paxillin, GREEN-TEA, EPITHELIAL-CELLS, METABOLIC SYNDROME, GROWTH-FACTOR, CANCER RISK, EXPRESSION, MIGRATION, KINASE, INHIBITION, APOPTOSIS

Abstract

Aims: Benign prostatic hyperplasia (BPH) is the most common urological disease that is characterized by the excessive growth of prostatic epithelial and stromal cells. Pharmacological therapy for BPH has limited use due to the many side effects so there is a need for new agents including natural compounds such as epigallocatechin-3-gallate (EGCG). This study was undertaken to assess the role of EGCG, suppressing the formation of BPH by reducing inflammation and oxidative stress, in cytoskeleton organization and ECM interactions via focal adhesions.